Benefits
Cardiovascular Health Support
CoQ10 is concentrated in cardiac tissue and supports normal cardiovascular function; CoQ10-class trials in heart-failure and blood-pressure settings are mixed and used generic CoQ10, not Ubiqsome specifically.
Mitochondrial Energy Production
CoQ10 is essential cofactor for mitochondrial electron transport chain — energy production. Supports cellular energy.
Antioxidant Activity
CoQ10 (especially reduced ubiquinol form) is potent lipid-soluble antioxidant — protects cell membranes and lipoproteins from oxidation.
Statin-Induced CoQ10 Depletion
Statin medications inhibit HMG-CoA reductase which produces CoQ10 precursors; statin users may benefit from CoQ10 supplementation. Particularly relevant for muscle symptoms ('statin myalgia').
Mechanism of action
Mitochondrial Electron Transport Cofactor
CoQ10 carries electrons in mitochondrial electron transport chain — essential for ATP synthesis. Foundation of energy production.
Phytosome® Bioavailability Enhancement
CoQ10 is highly lipophilic and crystalline at room temperature; standard absorption very poor; Phytosome addresses absorption challenge.
Lipid-Soluble Antioxidant
CoQ10 protects cell membranes and LDL particles from oxidation; lipid-soluble distinguishes from water-soluble antioxidants.
Cardiac Tissue Concentration
Cardiac muscle has highest CoQ10 concentration; supplementation supports cardiac function.
Endogenous Production Decline with Age
Endogenous CoQ10 production declines with age (peak in 20s, decline thereafter); supplementation may offset age-related decline.
Clinical trials
Q-SYMBIO trial of generic crystalline CoQ10 (ubiquinone) in chronic heart failure. (Mortensen et al. 2014, JACC Heart Failure) — this trial used generic CoQ10, NOT the Ubiqsome phytosome; included only as CoQ10-class context.
Chronic heart failure patients.
In this trial, generic CoQ10 reduced cardiovascular mortality and improved cardiac function — the most-cited CoQ10 heart-failure trial, but the result is for generic CoQ10, not Ubiqsome specifically.
Single- and repeated-dose pharmacokinetic study of Ubiqsome CoQ10 phytosome versus standard CoQ10 in healthy volunteers. (Petrangolini et al. 2019, Curr Drug Deliv)
Healthy adults.
Ubiqsome improved CoQ10 absorption/bioavailability — a surrogate (pharmacokinetic) endpoint; industry-funded (Indena).
Small double-blind, randomized, placebo-controlled trial using the Ubiqsome phytosome specifically. (Fogacci et al. 2024, J Clin Med)
Older adults with statin-associated asthenia.
Ubiqsome improved physical performance versus placebo — the one genuine clinical-outcome trial of this branded formulation, though small.